Common use of Financial Assistance Mechanism Clause in Contracts

Financial Assistance Mechanism. Cooperative Agreement Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post- award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds. CDC will provide substantial involvement beyond regular performance and financial monitoring during the project period. Substantial involvement means that applicants can expect federal programmatic partnership in carrying out the effort under the award. CDC will work in partnership with awardees to ensure the success of the cooperative agreement by:  Providing cross-site and awardee-specific surveillance technical assistance such as providing tools to identify drug poisonings using ICD-9-CM, ICD-10, text searches and ICD-10-CM, if implemented during the award period;  Providing technical assistance to revise annual work plans;  Assisting in advancing program activities to achieve project outcomes;  Providing scientific subject matter expertise and resources;  Collaborating with awardees to develop evaluation plans that align with CDC evaluation activities; Providing technical assistance on awardee’s evaluation and performance measurement plan; Providing technical assistance to define and operationalize performance measures;  Facilitating the sharing of information among grantees;  Participating in relevant meetings, committees, conference calls, and working groups related to the cooperative agreement requirements to achieve outcomes;  Coordinating communication and program linkages  Coordinating communication and program linkages with other CDC programs and Federal agencies, such as Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the HHS Office of the National Coordinator for Health Information Technology (ONC)  Translating and disseminating lessons learned through publications, meetings, surveillance measures and other means on promising and best practices to expand the evidence base. CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

Financial Assistance Mechanism. Cooperative Agreement Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post- post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds. CDC will provide substantial involvement beyond regular performance and financial monitoring during the project period. Substantial involvement means that applicants can expect federal programmatic partnership in carrying out the effort under the award. CDC will work in partnership with awardees to ensure the success of the cooperative agreement by:  Providing cross-site and awardee-specific surveillance technical assistance such as providing tools to identify drug poisonings using ICD-9-CM, ICD-10, text searches and ICD-10-CM, if implemented during the award period;  Providing technical assistance to revise annual work plans;  Assisting in advancing program activities to achieve project outcomes;  Providing scientific subject matter expertise and resources;  Collaborating with awardees to develop evaluation plans that align with CDC evaluation activities; Providing technical assistance on awardee’s evaluation and performance measurement plan; Providing technical assistance to define and operationalize performance measures;  Facilitating the sharing of information among grantees;  Participating in relevant meetings, committees, conference calls, and working groups related to the cooperative agreement requirements to achieve outcomes;  Coordinating communication and program linkages  Coordinating communication and program linkages with other CDC programs and Federal agencies, such as Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the HHS Office of the National Coordinator for Health Information Technology (ONC)  Translating and disseminating lessons learned through publications, meetings, surveillance measures and other means on promising and best practices to expand the evidence base. CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO. CDC activities in this NOFO are as follows:  Collaboration between program consultants across the division to provide coordination of program monitoring and technical assistance activities such as joint program calls, site visits, and regional consultations.  Team Leads, Project Officers, and Subject Matter Experts from across the division jointly plan and participate in trainings and other capacity building activities that address crosscutting strategic areas.  Resources and guides that address key programmatic needs across the FOA will be jointly developed and/or disseminated to ensure consistent messages with meeting grantee technical assistance needs.  Technical assistance in the areas of program implementation, fiscal and grants management, surveillance and epidemiology, health education and promotion, evaluation, community-clinical linkages, and environmental approaches will be coordinated across programs to ensure consistency and build awardee capacity.  CDC Chronic Project Officers will continue to identify collaboration and coordination opportunities through the NCCDPHP Regional Team meeting  Coordinated Program Directors meetings and Cancer Conferences will be prioritized to reduce burden on grantees  Establish program policies and guidelines collaboratively with grantees.  Facilitate the exchange of information and coordination, collaboration, and service integration between grantees and chronic disease counterparts.  Provide ongoing guidance, consultation and technical assistance to support the planning, implementation, monitoring, and evaluation of the activities listed within the components funded in this FOA.  Monitor grantee progress in implementing the program and work with grantees through email, conference calls, and site visits, and review of progress reports and other data reports to support program progress and program improvement.  Convene trainings, capacity building exercises, meetings, web forums, conference calls, and site visits with grantees.  Provide relevant scientific research findings, peer-reviewed publications, success stories, public health recommendations, and up-to-date clinical guidelines related to the FOA.  Provide eligible population estimates for available geographic units. Estimates are currently available at the national, state, and county level. Estimates can be found at: xxxx://xxx.xxxxxx.xxx/hhes/www/sahie/data/index.html.  Design, implement, and evaluate program implementation of screening and patient support services.  Provide strategies to work effectively with health care systems and community-based organizations to use available data and target populations to decrease disparities.  Provide guidance on practical application of appropriate Public Laws based on the program specific needs. These laws include; Public Law101-354, including amendments to the law, Public Health Service Act, (42 USC 280e-280e-4; Public Law 102-515), as amended and Public Health Service Act, [42 U.S.C. section247b (e) and (k)(2)], as amended.  Provide tools and methodologies to conduct linkages between the screening program data and central cancer registries data, and reporting registry stage data in the MDE.  Develop regular data monitoring feedback reports based on clinical data submissions to support data use for quality assurance, program improvement, and program monitoring and evaluation.  Evaluate, monitor, and report on progress toward meeting performance standards using interim progress reports, end of year reports, MDE reports, annual surveys, and others described in FOA.  Provide analytic datasets through CDC’s Research Data Center, restricted data access files for NPCR-sponsored registries, and a public use dataset.  Provide mechanisms to facilitate external data linkages through CDC’s National Death Index and Social Security Administration’s Administrative Databases.  Provide assistance with dissemination of information, including evaluation results, about awardee’s program efforts to the public and public health audiences. When appropriate, evaluation findings will be described for individual awardees by name.  Provide technical assistance and support to central cancer registries for electronic pathology, biomarkers and physician reporting/Meaningful Use efforts.  Develop and provide publicly available software programs for collecting, receiving, validating, processing, and analyzing cancer registry data.  Provide NPCR Program Standards and Program Manual to ensure standardized operations and data collection.  Collaborate with national partners and organizations to standardize the reporting of cancer, promote education for cancer registrars, and advocate for central cancer registries by actively participating as chairs/members of committees/workgroups.  Assess the quality of central cancer registry data by conducting NPCR-sponsored Data Quality Evaluations of central cancer registries.  Receive, evaluate, and disseminate cancer surveillance data received from central cancer registries through the NPCR Cancer Surveillance System.  Maintain online dissemination tools xxxx://xxx.xxx.xxx/cancer/npcr/tools.htm Technical Review Statement Response Requirement: The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to and approved, in writing, by the Grants Management Specialist/Grants Management Officer (GMS/GMO) noted in the CDC Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, July 31, 2018, will cause delay in programmatic progress and will adversely affect the future funding of this project.